Russell John Tait

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

The Walter and Eliza Hall Institute of Medical Research provides medical research services. It undertakes research in a range of areas, preventing and treating diseases including breast, ovarian and blood cancers, type 1 diabetes, rheumatoid arthritis, coeliac disease and malaria. The firm’s research areas include bioinformatics, cancer biology, cell death, cell signaling, clinical translation, epigenetics, genomics, immunology, and inflammation and vaccine development. The company was founded in 1915 and is headquartered in Melbourne, Australia.

Layerbio, Inc. develops bio erodible sustained-release technology for use in standard intraocular lens in cataract surgery. The private company is based in Lexington, MA. The company was founded in 2013 by Kenneth J. Mandell, Paula Hammond. Kenneth J. Mandell has been the CEO since 2013.

The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs.

Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia.

Part of Gilead Sciences, Inc., YM BioSciences Australia Pty Ltd. develops cancer treatment pharmaceuticals. The company is based in Melbourne, Australia.

Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.

Hatchtech Pty Ltd. operates as pharmaceutical product company. It offers Xeglyze lotion that is head lice treatment. The company was founded by Vernon Morrison Bowles in 2001 and is headquartered in in Melbourne, Australia.

AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008.

Fibrotech Therapeutics Pty Ltd develops novel drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as kidney disease, chronic heart failure, pulmonary fibrosis, and arthritis. The company was founded by Richard Ernest Gilbert, Darren James Kelly, Spencer J Williams, Steven C Zammit, David Stapleton, Henry Krum and Yuan Zhang in 2006 and is headquartered in Melbourne, Australia.

Yuuwa Capital Management Pty Ltd. ( Yuuwa Capital Management ) is a venture capital firm, founded in 2009 by Liddy McCall , James Williams, Matthew Macfarlane. The firm is headquartered in Bentley, Western Australia.

Part of Fitgenes Ltd., Fitgenes Australia Pty Ltd. provides education on Nutrigenomics. The company is based in Brisbane, Australia. Fitgenes Australia was acquired by Fitgenes Ltd.

Otifex Therapeutics Pty Ltd. develops treatment for ear diseases. The company was founded by Burkhard Franz and Colin Anderson in 2009 and is headquartered in Melbourne, Australia.

Sprout Pharmaceuticals, Inc. provides delivery of a treatment option for the unmet need of women with Hypoactive Sexual Desire Disorder. The company was founded by Cynthia E. Whitehead and Robert S. Whitehead on November 29, 2011 and is headquartered in Raleigh, NC.

Global Kinetics Pty Ltd. provides point of care measurement and reporting of Parkinson's disease motor symptoms. Its product includes Personal KinetiGraph (PKG), a wrist worn medical device which reminds the patient when they have taken Levodopa medication as prescribed by doctor. The company was founded by Robert Griffiths and Malcolm Horne in 2007 and is headquartered in Melbourne, Australia.

Nexgen Plants Pty Ltd. develops anti-viral technology solutions that enables virus resistant plant varieties to be developed for major food, fibre, energy and ornamental crops. The company was founded in 2013 and is headquartered in St. Lucia, Australia.

OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.

Yuuwa Capital LP seeks investment opportunities in the companies located in Australia primarily in Perth. The fund focuses on companies operating in the fields of software, information & communications technology ventures, life sciences and biotech sectors. It provides financing for early & seed stage capital requirements with investment size ranges between $1 million to $5 million.

Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel.

Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia.

Baker Heart & Diabetes Institute owns and operates a medical research institute. The company is headquartered in Melbourne, Australia.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.